Abstract:Lung cancer continues to pose a significant challenge as a prominent contributor to global cancer-related mortality. Despite the considerable strides made in therapeutic interventions within the past decade, a substantial population of patients diagnosed with non-small cell lung cancer (NSCLC) still face the grim reality of an incurable condition. In the realm of optimal management strategies for individuals afflicted with locally advanced, yet amenable to surgical resection, NSCLC, a therapeutic approach encompassing chemoradiation stands as a fundamental component. Significant strides have been made in the therapeutic landscape of NSCLC during the preceding two decades, facilitating an enhanced comprehension of the underlying disease biology, and mechanisms governing tumor progression, as well as advancements in early detection modalities and multimodal therapeutic interventions. Nevertheless, the overall rates of curative interventions and survival outcomes for NSCLC continue to exhibit a discouragingly low trajectory, particularly in the context of metastatic disease. Hence, the imperative for sustained research endeavors in the realm of novel pharmaceutical agents and combinatorial therapeutic approaches remains paramount, with the overarching objective of broadening the scope of clinical advantages conferred upon a wider demographic of patients, thereby fostering tangible improvements in outcomes pertaining to NSCLC. The primary objective of this review is to provide an all-encompassing examination encompassing the clinical application and synthetic routes of specific drugs, with the explicit aim of disseminating invaluable knowledge that can inform future research and development endeavors focused on NSCLC.

Targeted therapy of non-small cell lung cancer: mechanisms and clinical trials

Advances in Diagnosis and Treatment of HER2-positive Non-small Cell Lung Cancer

Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer

Targeted Therapy for Non-Small-cell Lung Cancer Using EGFR-TKIs

Understanding the treatment response and resistance to targeted therapies in non-small cell lung cancer: clinical insights and perspectives

Recent progress in targeted therapy for non-small cell lung cancer

Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy

Breakthrough in targeted therapy for non-small cell lung cancer

Biomarker-Targeted Therapies in Non–Small Cell Lung Cancer: Current Status and Perspectives

Targeted therapy in advanced non-small cell lung cancer: current advances and future trends

Advances of clinically approved small-molecule drugs for the treatment of non-small cell lung cancer

Targeted therapy for non‐small‐cell lung cancer: New insights into regulated cell death combined with immunotherapy

The emerging treatment landscape of targeted therapy in non-small-cell lung cancer

Target Therapy of Non-Small Cell Lung Cancer Directed by Biomarkers

Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives

A pharmacological exploration of targeted drug therapy in non-small cell lung cancer

Advances of Autophagy and EGFR-TKI Drug Resistance in the Treatment of Non-Small Cell Lung Cancer

Targeted drug therapy in non-small cell lung cancer: Clinical significance and possible solutions-Part I

Promising Combinatorial Therapeutic Strategies against Non-Small Cell Lung Cancer

Novel therapeutic strategies for rare mutations in non-small cell lung cancer

Targeting MET in Non-Small Cell Lung Cancer: an Ever-Expanding Territory